

Stefan Stårk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3243739/publications.pdf>

Version: 2024-02-01

276
papers

15,464
citations

23500

58
h-index

21474

114
g-index

314
all docs

314
docs citations

314
times ranked

17710
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages. <i>Clinical Research in Cardiology</i> , 2023, 112, 868-879.	1.5	4
2	Impact of cardiovascular risk factors on myocardial work – insights from the STAAB cohort study. <i>Journal of Human Hypertension</i> , 2022, 36, 235-245.	1.0	13
3	Establishing a cardiac training group for patients with heart failure: the “HIP-in-WA1/4rzburg” study. <i>Clinical Research in Cardiology</i> , 2022, 111, 406-415.	1.5	7
4	The association of general practitioners’ awareness of depression and anxiety with change in quality of life in heart failure patients: results of the prospective observational RECODE-HF cohort study. <i>Family Practice</i> , 2022, 39, 346-353.	0.8	1
5	Automated provision of clinical routine data for a complex clinical follow-up study: A data warehouse solution. <i>Health Informatics Journal</i> , 2022, 28, 146045822110580.	1.1	3
6	Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial. <i>Endocrine Connections</i> , 2022, , .	0.8	2
7	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 132-142.	2.9	30
8	AA amyloidosis in inflammatory active malignant paraganglioma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 137-138.	1.4	3
9	The First Year of Noninvasive Remote Telemonitoring in Chronic Heart Failure Is not Cost Saving but Improves Quality of Life: The Randomized Controlled CardioBBEAT Trial. <i>Telemedicine Journal and E-Health</i> , 2022, 28, 1613-1622.	1.6	5
10	Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 1245-1255.	1.5	14
11	Primary hyperaldosteronism induces congruent alterations of sodium homeostasis in different skeletal muscles: a ²³ Na-MRI study. <i>European Journal of Endocrinology</i> , 2022, 186, K33-K38.	1.9	8
12	Sex-specific bimodal clustering of left ventricular ejection fraction in patients with acute heart failure. <i>ESC Heart Failure</i> , 2022, 9, 786-790.	1.4	8
13	Telemonitoring of heart failure patients is reimbursed in Germany: challenges of real-world implementation remain. <i>European Heart Journal Digital Health</i> , 2022, 3, 121-122.	0.7	5
14	Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2626-2634.	1.4	11
15	Structured, Harmonized, and Interoperable Integration of Clinical Routine Data to Compute Heart Failure Risk Scores. <i>Life</i> , 2022, 12, 749.	1.1	0
16	Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1915-1923.	1.4	3
17	Prevalence and determinants of the precursor stages of heart failure: results from the population-based STAAB cohort study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 924-934.	0.8	23
18	Reply to: Dumping adherence: a person-centred response for primary care. <i>Family Practice</i> , 2021, 38, 197-198.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Applying the COM-B behaviour model to overcome barriers to heart failure self-care: A practical application of a conceptual framework for the development of complex interventions (ACHIEVE) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	10
20	The effect of spironolactone on diastolic function in haemodialysis patients. International Journal of Cardiovascular Imaging, 2021, 37, 1927-1936.	0.7	4
21	Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes. Journal of the American Heart Association, 2021, 10, e017822.	1.6	13
22	The <scp>Heart Failure Association Atlas</scp>: <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. European Journal of Heart Failure, 2021, 23, 906-914.	2.9	130
23	Hospitalizations for heart failure: still major differences between East and West Germany 30Âyears after reunification. ESC Heart Failure, 2021, 8, 2546-2555.	1.4	11
24	Adaptive antiâ€œmyocardial immune response following hospitalization for acute heart failure. ESC Heart Failure, 2021, 8, 3348-3353.	1.4	4
25	Left Ventricular Remodeling and Myocardial Work: Results From the Population-Based STAAB Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 669335.	1.1	16
26	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. JAMA Cardiology, 2021, 6, 706.	3.0	53
27	The Conspicuous Link between Ear, Brain and Heartâ€œCould Neurotrophin-Treatment of Age-Related Hearing Loss Help Prevent Alzheimerâ€™s Disease and Associated Amyloid Cardiomyopathy?. Biomolecules, 2021, 11, 900.	1.8	10
28	Corona Healthâ€™A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2021, 18, 7395.	1.2	21
29	Dynamics of Left Ventricular Myocardial Work in Patients Hospitalized for Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 1393-1403.	0.7	4
30	Functional versus morphological assessment of vascular age in patients with coronary heart disease. Scientific Reports, 2021, 11, 18164.	1.6	6
31	SektorÃ¼bergreifende Versorgung bei Herzinsuffizienz. , 2021, , 109-130.		3
32	Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study. BMC Endocrine Disorders, 2021, 21, 11.	0.9	2
33	Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failureâ€œthe COGNITION.MATTERS-HF cohort study. European Heart Journal, 2021, 42, 1569-1578.	1.0	31
34	Prevalence and determinants of systolic and diastolic cardiac dysfunction and heart failure in acute ischemic stroke patients: The SICFAIL study. ESC Heart Failure, 2021, 8, 1117-1129.	1.4	12
35	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	1.0	117
36	Long-term health sequelae and quality of life at least 6Âmonths after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP). Infection, 2021, 49, 1277-1287.	2.3	24

#	ARTICLE	IF	CITATIONS
37	Prognostic factors associated with quality of life in heart failure patients considering the use of the generic EQ-5D-5L,† in primary care: new follow-up results of the observational RECODE-HF study. BMC Family Practice, 2021, 22, 202.	2.9	0
38	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1919.	3.8	72
39	Efficacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-defibrillators: the randomized controlled ICD-FORUM trial. European Heart Journal, 2020, 41, 1203-1211.	1.0	18
40	Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2020, 13, 571-579.	1.4	8
41	Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial. The Lancet Digital Health, 2020, 2, e16-e24.	5.9	31
42	Myocardial work - correlation patterns and reference values from the population-based STAAB cohort study. PLoS ONE, 2020, 15, e0239684.	1.1	38
43	Coagulation factor XIII activity predicts left ventricular remodelling after acute myocardial infarction. ESC Heart Failure, 2020, 7, 2354-2364.	1.4	9
44	REPORT-HF reveals global inequalities in health care provision and prognosis of patients with acute heart failure. Cardiovascular Research, 2020, 116, e112-e114.	1.8	2
45	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke, 2020, 51, 2901-2909.	1.0	15
46	Incremental prognostic value of a novel metabolite-based biomarker score in congestive heart failure patients. ESC Heart Failure, 2020, 7, 3029-3039.	1.4	6
47	Association of depression and anxiety with adherence in primary care patients with heart failure—cross-sectional results of the observational RECODE-HF cohort study. Family Practice, 2020, 37, 695-702.	0.8	14
48	Utility of the integrated palliative care outcome scale (IPOS): a cross-sectional study in hospitalised patients with heart failure. European Journal of Cardiovascular Nursing, 2020, 19, 702-710.	0.4	20
49	Increased Catecholamine Levels and Inflammatory Mediators Alter Barrier Properties of Brain Microvascular Endothelial Cells in vitro. Frontiers in Cardiovascular Medicine, 2020, 7, 73.	1.1	27
50	Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. European Journal of Heart Failure, 2020, 22, 763-774.	2.9	24
51	The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure, 2020, 22, 638-645.	2.9	23
52	Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA-ADHF trial. ESC Heart Failure, 2020, 7, 973-983.	1.4	17
53	Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. ESC Heart Failure, 2020, 7, 942-952.	1.4	4
54	Unlocking the PACS DICOM Domain for its Use in Clinical Research Data Warehouses. Journal of Digital Imaging, 2020, 33, 1016-1025.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Factors associated with smoking cessation in patients with coronary heart disease: a cohort analysis of the German subset of EuroAspire IV survey. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 152.	0.7	12
56	Amyloidosis – the Diagnosis and Treatment of an Underdiagnosed Disease. <i>Deutsches Arzteblatt International</i> , 2020, 117, 159-166.	0.6	30
57	A Self-administered Version of the Functioning Assessment Short Test for Use in Population-based Studies: A Pilot Study. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2020, 16, 192-203.	0.6	3
58	Translating openEHR Models to FHIR. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 1415-1416.	0.2	4
59	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	2.9	11
60	Symptom patterns and clinical outcomes in women versus men with systolic heart failure and depression. <i>Clinical Research in Cardiology</i> , 2019, 108, 244-253.	1.5	23
61	Impact of Patient Beliefs on Blood Pressure Control in the General Population: Findings from the Population-Based STAAB Cohort Study. <i>International Journal of Hypertension</i> , 2019, 2019, 1-7.	0.5	3
62	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	0.6	299
63	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	0.6	108
64	Speckle tracking derived reference values of myocardial deformation and impact of cardiovascular risk factors – Results from the population-based STAAB cohort study. <i>PLoS ONE</i> , 2019, 14, e0221888.	1.1	5
65	Replicating medication trend studies using ad hoc information extraction in a clinical data warehouse. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 15.	1.5	3
66	A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. <i>Kidney International</i> , 2019, 95, 983-991.	2.6	64
67	Rationale and design of the EMPERIAL- Preserved and EMPERIAL- Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 932-942.	2.9	40
68	COPD and heart failure: differential diagnosis and comorbidity. <i>Herz</i> , 2019, 44, 502-508.	0.4	25
69	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.4	227
70	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
71	Physicians' lifestyle advice on primary and secondary cardiovascular disease prevention in Germany: A comparison between the STAAB cohort study and the German subset of EUROASPIRE IV. <i>European Journal of Preventive Cardiology</i> , 2019, , 204748731983821.	0.8	5
72	Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve Outcomes in patients with advanced) Tj ETQqO O O rgBT /Overlock 10 Heart Failure, 2019, 21, 676-684.	2.9	51

#	ARTICLE	IF	CITATIONS
73	Biallelic mutation in <i>MYH7</i> and <i>MYBPC3</i> leads to severe cardiomyopathy with left ventricular noncompaction phenotype. <i>Human Mutation</i> , 2019, 40, 1101-1114.	1.1	22
74	Segment-specific association of carotid-intima-media thickness with cardiovascular risk factors – findings from the STAAB cohort study. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 84.	0.7	9
75	Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1407-1416.	3.3	73
76	Higher prevalence of heart failure in rural regions: a population-based study covering 87% of German inhabitants. <i>Clinical Research in Cardiology</i> , 2019, 108, 1102-1106.	1.5	14
77	<p>HO-1 concentrations 24 hours after cardiac surgery are associated with the incidence of acute kidney injury: a prospective cohort study</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019, Volume 12, 9-18.	0.8	1
78	Information Extraction from Echocardiography Reports for a Clinical Follow-up Study – Comparison of Extracted Variables Intended for General Use in a Data Warehouse with Those Intended Specifically for the Study. <i>Methods of Information in Medicine</i> , 2019, 58, 140-150.	0.7	4
79	Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial. <i>Biomarkers in Medicine</i> , 2019, 13, 1493-1507.	0.6	5
80	Amyloidosis in Heart Failure. <i>Current Heart Failure Reports</i> , 2019, 16, 285-303.	1.3	26
81	Left Ventricular Structure in Patients With Mild-to-Moderate CKD – a Magnetic Resonance Imaging Study. <i>Kidney International Reports</i> , 2019, 4, 267-274.	0.4	7
82	The omega-3 index in patients with heart failure: A prospective cohort study. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2019, 140, 34-41.	1.0	13
83	Variations in cardiovascular risk factors in people with and without migration background in Germany – Results from the STAAB cohort study. <i>International Journal of Cardiology</i> , 2019, 286, 186-189.	0.8	3
84	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	2.5	22
85	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. <i>ESC Heart Failure</i> , 2019, 6, 174-181.	1.4	43
86	Increased myocardial sodium signal intensity in Conn’s syndrome detected by ²³ Na magnetic resonance imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 263-270.	0.5	32
87	Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. <i>Oncotarget</i> , 2019, 10, 3154-3165.	0.8	6
88	Implementation of a HL7-CQL Engine Using the Graph Database Neo4J. <i>Studies in Health Technology and Informatics</i> , 2019, 267, 46-51.	0.2	3
89	Query Translation Between AQL and CQL. <i>Studies in Health Technology and Informatics</i> , 2019, 264, 128-132.	0.2	3
90	Underestimated prevalence of heart failure in hospital inpatients: a comparison of ICD codes and discharge letter information. <i>Clinical Research in Cardiology</i> , 2018, 107, 778-787.	1.5	32

#	ARTICLE	IF	CITATIONS
91	Wild-type isolates of <i>Porphyromonas gingivalis</i> derived from periodontitis patients display major variability in platelet activation. <i>Journal of Clinical Periodontology</i> , 2018, 45, 693-700.	2.3	8
92	CRP genetic variants are associated with mortality and depressive symptoms in chronic heart failure patients. <i>Brain, Behavior, and Immunity</i> , 2018, 71, 133-141.	2.0	9
93	Importance of comorbidities in the treatment of primary care patients with heart failure—Baseline results of the observational RECODE-HF Study. <i>Family Practice</i> , 2018, 35, 481-487.	0.8	6
94	Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1362-1372.	0.4	24
95	New insights in efficacy of different dosages of enzyme replacement therapy due to treatment switch in Fabry disease. <i>Molecular Genetics and Metabolism</i> , 2018, 123, S84.	0.5	0
96	Secondary Prevention in Younger vs. Older Coronary Heart Disease Patients—Insights from the German Subset of the EUROASPIRE IV Survey. <i>International Journal of Behavioral Medicine</i> , 2018, 25, 283-293.	0.8	10
97	Heart failure with preserved ejection fraction: current management and future strategies. <i>Clinical Research in Cardiology</i> , 2018, 107, 1-19.	1.5	64
98	Impact of anti-infective periodontal therapy on parameters of vascular health. <i>Journal of Clinical Periodontology</i> , 2018, 45, 354-363.	2.3	13
99	Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study. <i>Clinical Research in Cardiology</i> , 2018, 107, 95-107.	1.5	15
100	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
101	Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 102-109.	0.6	10
102	Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function. <i>Journal of Thoracic Disease</i> , 2018, 10, 4966-4975.	0.6	8
103	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2018, 72, 929-936.	1.3	29
104	Reply. <i>JACC: Heart Failure</i> , 2018, 6, 889.	1.9	0
105	Myocardial Fibrosis Predicts 10-Year Survival in Patients Undergoing Aortic Valve Replacement. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007131.	1.3	33
106	Enhancing self-care adherence in patients with heart failure: a study protocol for developing a theory-based behaviour change intervention using the COM-B behaviour model (ACHIEVE study). <i>BMJ Open</i> , 2018, 8, e025907.	0.8	29
107	Ad Hoc Information Extraction for Clinical Data Warehouses. <i>Methods of Information in Medicine</i> , 2018, 57, e22-e29.	0.7	15
108	Chronic Heart Failure. <i>Deutsches Ärzteblatt International</i> , 2018, 115, 124-130.	0.6	22

#	ARTICLE	IF	CITATIONS
109	Renal effects of sacubitril/valsartan in patients with diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 519-521.	5.5	4
110	Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease. <i>Open Heart</i> , 2018, 5, e000803.	0.9	18
111	Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy. <i>Disease Markers</i> , 2018, 2018, 1-7.	0.6	9
112	The COMT-polymorphism is not associated with the incidence of acute kidney injury after cardiac surgery – a prospective cohort study. <i>BMC Nephrology</i> , 2018, 19, 34.	0.8	1
113	Impact of acquisition and interpretation on total inter-observer variability in echocardiography: results from the quality assurance program of the STAAB cohort study. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1057-1065.	0.7	23
114	Systolic characteristics and dynamic changes of the mitral valve in different grades of ischemic mitral regurgitation – insights from 3D transesophageal echocardiography. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 93.	0.7	6
115	Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. <i>Lancet</i> , 2018, 392, 1047-1057.	6.3	467
116	Cognitive Deficits and Related Brain Lesions in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 583-592.	1.9	66
117	Heart failure awareness: a cross-sectional study on misconceptions and educational opportunities. <i>Seminars in Cardiovascular Medicine</i> , 2018, 24, 9-15.	0.3	2
118	Prognostic significance of serial high-sensitivity troponin I measurements following acute cardiac decompensation-correlation with longer-term clinical outcomes and reverse remodelling. <i>International Journal of Cardiology</i> , 2017, 232, 199-207.	0.8	11
119	Echocardiographic Determinants of One-Year All-Cause Mortality in Patients With Chronic Heart Failure Complicated by Significant Functional Tricuspid Regurgitation. <i>Journal of Cardiac Failure</i> , 2017, 23, 434-443.	0.7	13
120	Frequency and prognostic impact of mid-expiratory flow reduction in stable patients six months after hospitalisation for heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2017, 227, 727-733.	0.8	3
121	Long-term treatment with ivabradine over 12 months in patients with chronic heart failure in clinical practice: Effect on symptoms, quality of life and hospitalizations. <i>International Journal of Cardiology</i> , 2017, 240, 258-264.	0.8	12
122	Characteristics and Course of Heart Failure Stages A and B and Determinants of Progression – design and rationale of the STAAB cohort study. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 468-479.	0.8	30
123	Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1168-1180.	0.8	13
124	Prognostic impact of diastolic dysfunction in systolic heart failure – A cross-project analysis from the German Competence Network Heart Failure. <i>Clinical Cardiology</i> , 2017, 40, 667-673.	0.7	13
125	Prognostic potential of midregional proadrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. <i>European Journal of Heart Failure</i> , 2017, 19, 1166-1175.	2.9	30
126	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133

#	ARTICLE	IF	CITATIONS
127	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <i>International Journal of Cardiology</i> , 2017, 243, 389-395.	0.8	26
128	Value of tissue Doppler-derived Tei index and two-dimensional speckle tracking imaging derived longitudinal strain on predicting outcome of patients with light-chain cardiac amyloidosis. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 837-845.	0.7	26
129	A functional variant of the neuropeptide S receptor gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (INH) Study. <i>European Journal of Heart Failure</i> , 2017, 19, 314-323.	2.9	13
130	TIMP-2*IGFBP7 (Nephrocheck®) Measurements at Intensive Care Unit Admission After Cardiac Surgery are Predictive for Acute Kidney Injury Within 48 Hours. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 456-467.	0.9	44
131	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
132	Epidemiology of heart failure in Germany: a retrospective database study. <i>Clinical Research in Cardiology</i> , 2017, 106, 913-922.	1.5	93
133	Treatment of chronic heart failure in Germany: a retrospective database study. <i>Clinical Research in Cardiology</i> , 2017, 106, 923-932.	1.5	26
134	Heart failure awareness survey in Germany: general knowledge on heart failure remains poor. <i>ESC Heart Failure</i> , 2017, 4, 224-231.	1.4	18
135	Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation – Results from the German EuroAspire IV cohort. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 108.	0.7	19
136	Factors associated with general practitioners' awareness of depression in primary care patients with heart failure: baseline-results from the observational RECODE-HF study. <i>BMC Family Practice</i> , 2017, 18, 71.	2.9	10
137	Feasibility and diagnostic accuracy of point-of-care handheld echocardiography in acute ischemic stroke patients – a pilot study. <i>BMC Neurology</i> , 2017, 17, 159.	0.8	9
138	Control of cardiovascular risk factors and its determinants in the general population – findings from the STAAB cohort study. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 276.	0.7	24
139	General practitioners' awareness of depressive symptomatology is not associated with quality of life in heart failure patients – cross-sectional results of the observational RECODE-HF Study. <i>BMC Family Practice</i> , 2017, 18, 100.	2.9	5
140	Patient's and physician's awareness of kidney disease in coronary heart disease patients – a cross-sectional analysis of the German subset of the EUROASPIRE IV survey. <i>BMC Nephrology</i> , 2017, 18, 321.	0.8	18
141	Extending the Query Language of a Data Warehouse for Patient Recruitment. <i>Studies in Health Technology and Informatics</i> , 2017, 243, 152-156.	0.2	3
142	Data Linkage from Clinical to Study Databases via an R Data Warehouse User Interface. <i>Methods of Information in Medicine</i> , 2016, 55, 381-386.	0.7	9
143	Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2683.	3.8	226
144	Proposals for enhanced health risk assessment and stratification in an integrated care scenario. <i>BMJ Open</i> , 2016, 6, e010301.	0.8	61

#	ARTICLE	IF	CITATIONS
145	The septal bulge—an early echocardiographic sign in hypertensive heart disease. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 70-80.	2.3	34
146	Prevalence of severe mitral regurgitation eligible for edge-to-edge mitral valve repair (MitraClip). <i>Clinical Research in Cardiology</i> , 2016, 105, 699-709.	1.5	16
147	Systematic Echocardiographic Evaluation of Mitral Valve Regurgitation for Transcatheter Edge-to-Edge Repair. <i>Echocardiography</i> , 2016, 33, 1069-1079.	0.3	2
148	What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. <i>European Journal of Heart Failure</i> , 2016, 18, 66-70.	2.9	24
149	Does Simulation-Based Training Improve Procedural Skills of Beginners in Interventional Cardiology?—A Stratified Randomized Study. <i>Journal of Interventional Cardiology</i> , 2016, 29, 75-82.	0.5	29
150	Heart failure epidemiology 2000—2013: insights from the German Federal Health Monitoring System. <i>European Journal of Heart Failure</i> , 2016, 18, 1009-1018.	2.9	113
151	High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	55
152	Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 264-274.	0.7	53
153	Longitudinal strain bull's eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy. <i>European Journal of Medical Research</i> , 2016, 21, 21.	0.9	44
154	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	0.8	772
155	High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 69-73.	0.8	22
156	What does it take to make integrated care work?. <i>International Journal of Integrated Care</i> , 2016, 16, 113.	0.1	2
157	Health risk assessment and stratification in an integrated care scenario. <i>International Journal of Integrated Care</i> , 2016, 16, 322.	0.1	3
158	Validation of the FEW16 questionnaire for the assessment of physical well-being in patients with heart failure with reduced ejection fraction: results from the CIBIS-ELD study. <i>ESC Heart Failure</i> , 2015, 2, 194-203.	1.4	4
159	Fine-grained information extraction from German transthoracic echocardiography reports. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 91.	1.5	20
160	First outline and baseline data of a randomized, controlled multicenter trial to evaluate the health economic impact of home telemonitoring in chronic heart failure — CardioBBEAT. <i>Trials</i> , 2015, 16, 343.	0.7	15
161	The cardiomyopathy in Friedreich's ataxia — New biomarker for staging cardiac involvement. <i>International Journal of Cardiology</i> , 2015, 194, 50-57.	0.8	42
162	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101

#	ARTICLE	IF	CITATIONS
163	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. <i>Journal of Cardiac Failure</i> , 2015, 21, 208-216.	0.7	17
164	Reverse epidemiology in different stages of heart failure. <i>International Journal of Cardiology</i> , 2015, 184, 216-224.	0.8	18
165	The role of circulatory power and cardiac reserve in reverse epidemiology – Assessing heart failure severity. <i>International Journal of Cardiology</i> , 2015, 191, 48-49.	0.8	1
166	Depressive symptoms in heart failure: Independent prognostic factor or marker of functional status?. <i>Journal of Psychosomatic Research</i> , 2015, 78, 569-572.	1.2	13
167	Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. <i>European Journal of Heart Failure</i> , 2015, 17, 442-452.	2.9	103
168	Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. <i>Clinical Research in Cardiology</i> , 2015, 104, 304-309.	1.5	13
169	Comparative Potential of the 2-Item Versus the 9-Item Patient Health Questionnaire to Predict Death or Rehospitalization in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 464-472.	1.6	41
170	Journey of a patient with chronic thromboembolic pulmonary hypertension. <i>European Journal of Medical Research</i> , 2015, 20, 20.	0.9	2
171	Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1401-1412.	0.7	20
172	Electrical Changes in Resting, Exercise, and Holter Electrocardiography in Fabry Cardiomyopathy. <i>JIMD Reports</i> , 2015, , 19-28.	0.7	8
173	Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2015, 15, 83.	0.8	11
174	Fabry disease and the heart. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 195-204.	2.2	62
175	Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy. <i>PLoS ONE</i> , 2015, 10, e0140627.	1.1	27
176	Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 400-405.	0.4	26
177	Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. <i>European Journal of Heart Failure</i> , 2014, 16, 1273-1282.	2.9	66
178	Gene Mutations Versus Clinically Relevant Phenotypes. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 8-16.	5.1	118
179	Effects of structured heart failure disease management on mortality and morbidity depend on patients' mood: results from the Interdisciplinary Network for Heart Failure Study. <i>European Journal of Heart Failure</i> , 2014, 16, 1133-1141.	2.9	18
180	Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 837-849.	3.0	56

#	ARTICLE	IF	CITATIONS
181	Screening for mental disorders in heart failure patients using computer-adaptive tests. <i>Quality of Life Research</i> , 2014, 23, 1609-1618.	1.5	27
182	Clinical characteristics, treatment and survival in patients with systolic heart failure – Comparative assessment of a Chinese and a German cohort. <i>International Journal of Cardiology</i> , 2014, 176, 1388-1390.	0.8	4
183	A Copeptin-Based Classification of the Osmoregulatory Defects in the Syndrome of Inappropriate Antidiuresis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2376-2383.	3.0	62
184	Relation of Burden of Myocardial Fibrosis to Malignant Ventricular Arrhythmias and Outcomes in Fabry Disease. <i>American Journal of Cardiology</i> , 2014, 114, 895-900.	0.7	112
185	Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial. <i>European Journal of Heart Failure</i> , 2014, 16, 907-914.	2.9	25
186	Predictive Value of Assessing Diastolic Strain Rate on Survival in Cardiac Amyloidosis Patients with Preserved Ejection Fraction. <i>PLoS ONE</i> , 2014, 9, e115910.	1.1	31
187	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	2.9	75
188	Airway obstruction in systolic heart failure – COPD or congestion?. <i>International Journal of Cardiology</i> , 2013, 168, 1910-1916.	0.8	79
189	Recognition of depression and anxiety and their association with quality of life, hospitalization and mortality in primary care patients with heart failure – study protocol of a longitudinal observation study. <i>BMC Family Practice</i> , 2013, 14, 180.	2.9	19
190	Reply to: Risk assessment of depression by questionnaire for patients with heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 3129.	0.8	0
191	Airway obstruction in patients with cardiac diseases. <i>International Journal of Cardiology</i> , 2013, 168, 5109.	0.8	0
192	Using Simple Imaging Markers to Predict Prognosis in Patients With Aortic Valve Stenosis and Unacceptable High Risk for Operation. <i>American Journal of Cardiology</i> , 2013, 112, 1819-1827.	0.7	5
193	Generic and disease-specific health-related quality of life in patients with chronic systolic heart failure: impact of depression. <i>Clinical Research in Cardiology</i> , 2013, 102, 269-278.	1.5	49
194	Incidence rates and predictors of major and minor depression in patients with heart failure. <i>International Journal of Cardiology</i> , 2013, 167, 502-507.	0.8	60
195	Prognostic impact of subclinical thyroid dysfunction in heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 300-305.	0.8	57
196	Reply to: Questionnaire survey on depression for patients with heart failure: Validation for selecting appropriate cut-off points. <i>International Journal of Cardiology</i> , 2013, 162, 132.	0.8	1
197	Effect of Combined Systolic and Diastolic Functional Parameter Assessment for Differentiation of Cardiac Amyloidosis From Other Causes of Concentric Left Ventricular Hypertrophy. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 1066-1072.	1.3	150
198	Cardiomyopathy of Friedreich Ataxia. <i>Journal of Neurochemistry</i> , 2013, 126, 88-93.	2.1	82

#	ARTICLE	IF	CITATIONS
199	Long-term outcome of enzyme replacement therapy in advanced <sc>F</sc> disease: evidence for disease progression towards serious complications. Journal of Internal Medicine, 2013, 274, 331-341.	2.7	182
200	A rare case of Marfan syndrome and concomitant alpha-1 antitrypsin deficiency [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1370-1371.	0.6	0
201	Impact of Regional Left Ventricular Function on Outcome for Patients with AL Amyloidosis. PLoS ONE, 2013, 8, e56923.	1.1	23
202	Differentiation Between Fresh and Old Left Ventricular Thrombi by Deformation Imaging. Circulation: Cardiovascular Imaging, 2012, 5, 667-675.	1.3	20
203	Mode of Action and Effects of Standardized Collaborative Disease Management on Mortality and Morbidity in Patients With Systolic Heart Failure. Circulation: Heart Failure, 2012, 5, 25-35.	1.6	209
204	The Heart in Friedreich Ataxia. Circulation, 2012, 125, 1626-1634.	1.6	119
205	Dysnatraemia in heart failure. European Journal of Heart Failure, 2012, 14, 1147-1154.	2.9	53
206	Left Ventricular Noncompaction Cardiomyopathy. Circulation, 2012, 126, e240-3.	1.6	27
207	Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease. International Journal of Cardiology, 2012, 156, 289-294.	0.8	33
208	Serial cardiac imaging in peripartum cardiomyopathy. International Journal of Cardiology, 2012, 157, 308-309.	0.8	3
209	GOLD or lower limit of normal definition? a letter and authors'™ response. Respiratory Research, 2012, 13, 61.	1.4	4
210	The Impact of Heart Failure on the Classification of COPD Severity. Journal of Cardiac Failure, 2012, 18, 637-644.	0.7	38
211	"GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study". Respiratory Research, 2012, 13, 13.	1.4	134
212	Activated protein C in patients with septic shock: a consecutive case series. International Journal of Clinical Pharmacy, 2012, 34, 23-26.	1.0	3
213	Resource use and costs in systolic heart failure according to disease severity: a pooled analysis from the German Competence Network Heart Failure. Zeitschrift Fur Gesundheitswissenschaften, 2012, 20, 23-30.	0.8	14
214	Towards a Fruitful Discussion on a Multi-faceted and Complex Topic in Echocardiography: Response to the Letter to the Editor. Journal of the American Society of Echocardiography, 2011, 24, 107-108.	1.2	0
215	Somatic correlates of comorbid major depression in patients with systolic heart failure. International Journal of Cardiology, 2011, 147, 66-73.	0.8	52
216	Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. Thrombosis and Haemostasis, 2011, 106, 141-148.	1.8	15

#	ARTICLE	IF	CITATIONS
217	Prominent Papillary Muscles in Fabry Disease: A Diagnostic Marker?. <i>Ultrasound in Medicine and Biology</i> , 2011, 37, 37-43.	0.7	53
218	Echocardiographic Evaluation of Systolic and Diastolic Function in Patients With Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2011, 108, 591-598.	0.7	46
219	Low-Gradient Aortic Valve Stenosis. <i>Journal of the American College of Cardiology</i> , 2011, 58, 402-412.	1.2	265
220	Remodeling of the infarct territory in the time course of infarct healing in humans. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2011, 24, 277-284.	1.1	9
221	Androgen Deficiency in Heart Failure. <i>Current Heart Failure Reports</i> , 2011, 8, 131-139.	1.3	9
222	Heart failure therapy in diabetic patients- comparison with the recent ESC/EASD guideline. <i>Cardiovascular Diabetology</i> , 2011, 10, 15.	2.7	5
223	Cardiac Magnetic Resonance Imaging Findings in 20-year Survivors of Mediastinal Radiotherapy for Hodgkin's Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1117-1123.	0.4	68
224	Copeptin in the Differential Diagnosis of the Polydipsia-Polyuria Syndrome—Revisiting the Direct and Indirect Water Deprivation Tests. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1506-1515.	1.8	147
225	Striking Increases in Carotid Artery Wall Thickness in Healthy Subjects. <i>Cerebrovascular Diseases</i> , 2010, 30, 448-455.	0.8	5
226	Cardiac β_1 -adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titration Course, and Survival (ETiCS) Study. <i>European Journal of Heart Failure</i> , 2010, 12, 753-762.	2.9	63
227	The Different Faces of Echocardiographic Left Ventricular Hypertrophy: Clues to the Etiology. <i>Journal of the American Society of Echocardiography</i> , 2010, 23, 793-801.	1.2	36
228	Disease Management for Nondepressed Heart Failure Patients Only. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2049.	1.2	0
229	Impact of depression on quality of life assessment in heart failure. <i>International Journal of Cardiology</i> , 2010, 142, 133-137.	0.8	38
230	A network against failing hearts—Introducing the German "Competence Network Heart Failure". <i>International Journal of Cardiology</i> , 2010, 145, 135-138.	0.8	39
231	Utility and Limitations of the Traditional Diagnostic Approach to Hyponatremia: A Diagnostic Study. <i>American Journal of Medicine</i> , 2010, 123, 652-657.	0.6	113
232	Electrocardiography and Outcome in Patients with Diabetes Mellitus on Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 394-400.	2.2	51
233	Copeptin in the Differential Diagnosis of Hyponatremia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 123-129.	1.8	179
234	Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis. <i>Circulation</i> , 2009, 120, 577-584.	1.6	619

#	ARTICLE	IF	CITATIONS
235	Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy. <i>Circulation</i> , 2009, 119, 524-529.	1.6	422
236	Reverse Epidemiology in Systolic and Nonsystolic Heart Failure. <i>Circulation: Heart Failure</i> , 2009, 2, 563-571.	1.6	95
237	Biomarkers in Heart Failure – Better than History or Echocardiography?. <i>Herz</i> , 2009, 34, 581-588.	0.4	10
238	Depression and Disease Severity as Predictors of Health-Related Quality of Life in Patients With Chronic Heart Failure – A Structural Equation Modeling Approach. <i>Journal of Cardiac Failure</i> , 2009, 15, 286-292.e2.	0.7	82
239	The Biomaterialbank of the German Competence Network of Heart Failure (CNHF) is a valuable resource for biomedical and genetic research. <i>International Journal of Cardiology</i> , 2009, 136, 108-111.	0.8	10
240	Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. <i>Journal of Hypertension</i> , 2009, 27, 2483-2491.	0.3	74
241	Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. <i>Journal of Internal Medicine</i> , 2008, 264, 245-253.	2.7	41
242	Sleep-Disordered Breathing and Heart Failure. <i>Trends in Cardiovascular Medicine</i> , 2008, 18, 240-247.	2.3	13
243	Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality. <i>European Journal of Heart Failure</i> , 2008, 10, 388-395.	2.9	60
244	Progression of Left Ventricular Functional Abnormalities in Hypertensive Patients with Heart Failure: An Ultrasonic Two-Dimensional Speckle Tracking Study. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 1309-1317.	1.2	110
245	Value of Fractional Uric Acid Excretion in Differential Diagnosis of Hyponatremic Patients on Diuretics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2991-2997.	1.8	152
246	Effect of contrast application on interpretability and diagnostic value of dobutamine stress echocardiography in patients with intermediate coronary lesions: comparison with myocardial fractional flow reserve. <i>European Heart Journal</i> , 2008, 29, 2536-2543.	1.0	30
247	Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure A prospective cohort study. <i>European Journal of Heart Failure</i> , 2008, 10, 1236-1245.	2.9	60
248	Contemplative meditation reduces ambulatory blood pressure and stress-induced hypertension: a randomized pilot trial. <i>Journal of Human Hypertension</i> , 2008, 22, 138-140.	1.0	35
249	ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. <i>Thrombosis and Haemostasis</i> , 2008, 100, 618-625.	1.8	28
250	ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. <i>Thrombosis and Haemostasis</i> , 2008, 100, 618-25.	1.8	5
251	Depression and survival in chronic heart failure: Does gender play a role?. <i>European Journal of Heart Failure</i> , 2007, 9, 1018-1023.	2.9	66
252	Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). <i>European Journal of Heart Failure</i> , 2007, 9, 1212-1222.	2.9	78

#	ARTICLE	IF	CITATIONS
253	A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. <i>European Heart Journal</i> , 2007, 28, 3020-3026.	1.0	90
254	Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure. <i>Circulation</i> , 2007, 115, 1754-1761.	1.6	262
255	Is health-related quality of life an independent predictor of survival in patients with chronic heart failure?. <i>Journal of Psychosomatic Research</i> , 2007, 63, 533-538.	1.2	51
256	Low levels of adiponectin predict worsening of arterial morphology and function. <i>Atherosclerosis</i> , 2007, 194, e147-e153.	0.4	35
257	A Novel Fluorescence Method for the Rapid Detection of Functional β_1 -Adrenergic Receptor Autoantibodies in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 423-431.	1.2	86
258	Prediction of Mortality Risk in the Elderly. <i>American Journal of Medicine</i> , 2006, 119, 519-525.	0.6	122
259	Stimulating autoantibodies directed against the cardiac β_1 -adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. <i>American Heart Journal</i> , 2006, 152, 697-704.	1.2	124
260	Assessment of Cardiac Allograft Vasculopathy Late After Heart Transplantation: When Is Coronary Angiography Necessary?. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1103-1108.	0.3	48
261	Clinical validation of the gated blood pool SPECT QBSA [®] processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. <i>International Journal of Cardiovascular Imaging</i> , 2006, 22, 407-416.	0.7	33
262	Assessment of the contractile reserve in patients with intermediate coronary lesions: a strain rate imaging study validated by invasive myocardial fractional flow reserve. <i>European Heart Journal</i> , 2006, 28, 1425-1432.	1.0	43
263	The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. <i>European Heart Journal</i> , 2005, 26, 1221-1227.	1.0	214
264	Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients ? The IMPROVED multi-centre study. <i>European Heart Journal</i> , 2004, 25, 1626-1634.	1.0	56
265	Carotid Artery Plaque Burden, Stiffness, and Mortality Risk in Elderly Men. <i>Circulation</i> , 2004, 110, 344-348.	1.6	201
266	Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. <i>Trends in Endocrinology and Metabolism</i> , 2004, 15, 66-72.	3.1	55
267	Relationship between right ventricular ejection fraction and maximum exercise oxygen consumption: a methodological study in chronic heart failure patients. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 644-649.	1.4	11
268	Effect of dietary supplementation with ω -3 fatty acids on progression of atherosclerosis in carotid arteries. <i>Cardiovascular Research</i> , 2002, 54, 183-190.	1.8	81
269	The effect of 17β -estradiol on MCP-1 serum levels in postmenopausal women. <i>Cardiovascular Research</i> , 2002, 53, 642-649.	1.8	68
270	The effect of 17β -estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. <i>Atherosclerosis</i> , 2002, 165, 301-307.	0.4	91

#	ARTICLE	IF	CITATIONS
271	Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries. <i>Maturitas</i> , 2002, 41, 51-60.	1.0	31
272	Endothelial function of the popliteal artery in patients with coronary artery disease. <i>Atherosclerosis</i> , 2001, 155, 187-193.	0.4	22
273	Influence of 17 β -oestradiol on blood pressure of postmenopausal women at high vascular risk. <i>Journal of Hypertension</i> , 2001, 19, 2135-2142.	0.3	16
274	Bone Sialoprotein is a Specific Biochemical Marker of Bone Metabolism in Postmenopausal Women: A Randomized 1-Year Study. <i>Osteoporosis International</i> , 2000, 11, 790-796.	1.3	13
275	Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1789-1796.	1.2	42
276	Short term effects of ω -3 fatty acids on the radial artery of patients with coronary artery disease. <i>Atherosclerosis</i> , 1998, 140, 181-186.	0.4	22